Codexis, Inc. (NASDAQ:CDXS) Director Patrick Y. Yang sold 50,000 shares of the stock in a transaction dated Wednesday, September 19th. The shares were sold at an average price of $18.20, for a total transaction of $910,000.00. Following the transaction, the director now owns 128,817 shares of the company’s stock, valued at approximately $2,344,469.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Patrick Y. Yang also recently made the following trade(s):

  • On Thursday, August 16th, Patrick Y. Yang sold 150,340 shares of Codexis stock. The shares were sold at an average price of $14.45, for a total transaction of $2,172,413.00.

Shares of CDXS stock traded down $0.08 during trading hours on Friday, reaching $15.33. The stock had a trading volume of 540,421 shares, compared to its average volume of 379,159. Codexis, Inc. has a 12 month low of $5.70 and a 12 month high of $19.60. The firm has a market capitalization of $917.74 million, a P/E ratio of -30.66 and a beta of -2.07.

Codexis (NASDAQ:CDXS) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $13.54 million for the quarter, compared to the consensus estimate of $11.87 million. Codexis had a negative net margin of 29.83% and a negative return on equity of 61.93%. Analysts anticipate that Codexis, Inc. will post -0.2 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of CDXS. Wells Fargo & Company MN raised its stake in shares of Codexis by 17.9% during the first quarter. Wells Fargo & Company MN now owns 1,181,327 shares of the biotechnology company’s stock worth $12,995,000 after acquiring an additional 179,241 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Codexis in the first quarter worth approximately $148,000. Baillie Gifford & Co. grew its holdings in shares of Codexis by 25.0% in the first quarter. Baillie Gifford & Co. now owns 2,302,979 shares of the biotechnology company’s stock worth $25,332,000 after purchasing an additional 460,578 shares during the last quarter. Spark Investment Management LLC bought a new position in shares of Codexis in the first quarter worth approximately $1,405,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Codexis by 30.5% in the first quarter. New York State Common Retirement Fund now owns 44,900 shares of the biotechnology company’s stock worth $494,000 after purchasing an additional 10,500 shares during the last quarter. 77.35% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on the stock. Craig Hallum increased their target price on shares of Codexis from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 5th. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a research report on Wednesday, August 29th. Cowen assumed coverage on shares of Codexis in a research report on Tuesday, June 19th. They set an “outperform” rating and a $18.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Codexis from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Thursday, August 16th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Codexis currently has a consensus rating of “Buy” and an average target price of $15.50.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Further Reading: How are the companies in the S&P 500 selected?

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.